A venture capital firm with offices in USA and Japan, generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.

The firm invests in advanced therapeutics, digital health, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high-quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A real estate company / family office investment vehicle based in North America is looking to expand their investments into the healthcare field. The firm is looking to invest $4-5 million into various startups in the upcoming year, seeking opportunities at the Seed to Series A range. The firm is willing to both lead and follow on investments they make and are looking for opportunities solely within the USA and Canada.

The firm is looking for opportunities within the Medical Device, Digital Health, Diagnostics, and Biotech R&D Spaces. Specifically, the firm is looking for technologies that can help physicians. Examples of such technologies include: telemedicine, clinical trial services for physicians, and digital health solutions to help patient engagement. The firm is also interested in new medical devices and diagnostic technologies that are in the clinical trial stage. The firm is currently not interested in therapeutics.

The firm is looking for a strong management team who has a strong vision and development plan for the technology of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture firm is focused on pre-seed and seed stage investments, typically with an initially investment of $500k to $1m as part of the company’s first institutional funding. The firm prefers companies located in the US and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though they’re comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen fund based in Western Europe with LPs who were successful dot-com entrepreneurs is a hands-on investor in early-stage companies, historically in the tech sector but the firm now also invests in the life science space. The firm’s investments are generally EUR 3-5 million and are focused on Southeast Europe. The firm has successfully invested in over 60 companies.

The firm is opportunistic in the life science and healthcare tech space but prefers market evaluation with business models focused on B2B; previous investments include bio-informatic technologies and point of care diagnostics. The firm will consider opportunities in any indication area and is open to investing in technologies at an early development stage, prior to regulatory approval.

The firm has a management team with a very hands-on approach and often makes majority investments. The firm generally does not tranche its financings.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical company headquartered in China’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading. Its investment subsidiary has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development. The firm also invests in funds. The firm’s allocation size is decided case by case.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilar. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An international family of venture capital funds that invests in early-stage, high-growth life science and health technology companies in the US, UK, and Europe. The firm invests via a two fund structure, and is currently investing out of one Europe-based fund, and is actively raising a USA fund to focus on investing in USA-based companies. The EU fund primarily provides Series A financing in the range of £2-5M. The EU fund is actively seeking new investment opportunities in the UK and Europe. In the USA, Epidarex is interested in Seed and Series A opportunities.

The firm is currently seeking to invest in novel early stage biotech therapeutic and diagnostic, medical devices and pharmaceuticals. The firm is opportunistic in terms of subsectors and indications. The firm is also interested in other areas such as personalized medicine, healthcare IT and services. For therapeutics, the firm focuses on products in pre-clinical and early clinical and will consider orphan indications.

The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the USA is actively investing in Seed to Series A rounds. In addition to providing equity capital, the firm will also assist companies with intellectual property. The firm is open to opportunities in North America (USA and Canada).

The firm is interested in early-stage medical technology, diagnostics, and digital health/wellness companies and is open to medical devices of all regulatory pathways including 510k and PMA. The firm strongly prefers products that have received FDA clearance but is open to working with pre-FDA products. The firm will generally not pursue opportunities in biopharma therapeutics.

The firm to work with privately owned companies that are backed by an experienced management team. The firm likes to form syndicates and prefers co-investing in financing rounds, but the firm can lead rounds as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.